aminolevulinic acid has been researched along with Malignant Melanoma in 40 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent reports have suggested that 5-aminolevulinic acid (5-ALA), which is a precursor to protoporphyrin IX (PpIX), leads to selective accumulation of PpIX in tumor cells and acts as a radiation sensitizer in vitro and in vivo in mouse models of melanoma, glioma, and colon cancer." | 7.96 | DNA Strand Break Properties of Protoporphyrin IX by X-Ray Irradiation against Melanoma. ( Doi, M; Hasegawa, T; Iwahashi, H; Moriyama, A; Nagasawa, S; Takahashi, J, 2020) |
| "The present research work describes the use of photodynamic therapy (PDT) of drug 5-aminolevulinic acid (5-ALA) conjugated with microbial synthesised silver nanoparticles on skin melanoma (B16F10) and epidermoid carcinoma (A431) cell lines." | 7.91 | Photodynamic therapy on skin melanoma and epidermoid carcinoma cells using conjugated 5-aminolevulinic acid with microbial synthesised silver nanoparticles. ( Sanjay, KR; Shivashankarappa, A, 2019) |
| " In this study, we investigated the transformation of macrophages and dendritic cells (DCs) in the tumor microenvironment during 5-aminolevulinic acid (5-ALA)-mediated SDT in mice transplanted with B16F10 melanomas." | 7.80 | 5-Aminolevulinic acid-mediated sonodynamic therapy reverses macrophage and dendritic cell passivity in murine melanoma xenografts. ( Cao, W; Gao, Z; Gu, C; Hu, Z; Wang, S; Wang, X; Zheng, J, 2014) |
| "We report the case of a 82-year-old man who, after multiple treatments with aminolevulinic acid photodynamic therapy for solar keratoses and superficial squamous cell carcinomas, developed malignant melanoma at the exposed site on the scalp." | 7.69 | Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. ( Fink-Puches, R; Kerl, H; Reimann-Weber, A; Wolf, P, 1997) |
| "5-Aminolevulinic acid is a prodrug clinically approved for PDT." | 5.91 | Enhanced Delivery of 5-Aminolevulinic Acid by Lecithin Invasomes in 3D Melanoma Cancer Model. ( Caputo, A; Filotico, R; Gaballo, A; Gallo, N; Guida, G; Nito, A; Nobile, C; Piccirillo, C; Quarta, A; Ragusa, A; Salvatore, L; Zito, A, 2023) |
| "Silver nanoparticles were synthesised using the bacterial strain Bacillus licheniformis." | 5.51 | Photodynamic therapy on skin melanoma and epidermoid carcinoma cells using conjugated 5-aminolevulinic acid with microbial synthesised silver nanoparticles. ( Sanjay, KR; Shivashankarappa, A, 2019) |
| "Recent reports have suggested that 5-aminolevulinic acid (5-ALA), which is a precursor to protoporphyrin IX (PpIX), leads to selective accumulation of PpIX in tumor cells and acts as a radiation sensitizer in vitro and in vivo in mouse models of melanoma, glioma, and colon cancer." | 3.96 | DNA Strand Break Properties of Protoporphyrin IX by X-Ray Irradiation against Melanoma. ( Doi, M; Hasegawa, T; Iwahashi, H; Moriyama, A; Nagasawa, S; Takahashi, J, 2020) |
| "The present research work describes the use of photodynamic therapy (PDT) of drug 5-aminolevulinic acid (5-ALA) conjugated with microbial synthesised silver nanoparticles on skin melanoma (B16F10) and epidermoid carcinoma (A431) cell lines." | 3.91 | Photodynamic therapy on skin melanoma and epidermoid carcinoma cells using conjugated 5-aminolevulinic acid with microbial synthesised silver nanoparticles. ( Sanjay, KR; Shivashankarappa, A, 2019) |
| " In this study, we investigated the transformation of macrophages and dendritic cells (DCs) in the tumor microenvironment during 5-aminolevulinic acid (5-ALA)-mediated SDT in mice transplanted with B16F10 melanomas." | 3.80 | 5-Aminolevulinic acid-mediated sonodynamic therapy reverses macrophage and dendritic cell passivity in murine melanoma xenografts. ( Cao, W; Gao, Z; Gu, C; Hu, Z; Wang, S; Wang, X; Zheng, J, 2014) |
| "Based on the observation that 5-aminolevulinic acid (ALA) induces the expression of heme oxygenase-1 (HO-1) in cultured melanoma cells, the role of HO-1 on the effectiveness of 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) was examined." | 3.74 | Inhibition of heme oxygenase-1 increases responsiveness of melanoma cells to ALA-based photodynamic therapy. ( Biesalski, HK; Flaccus, A; Frank, J; Lambert, C; Lornejad-Schäfer, MR; Schöffl, H, 2007) |
| "We report the case of a 82-year-old man who, after multiple treatments with aminolevulinic acid photodynamic therapy for solar keratoses and superficial squamous cell carcinomas, developed malignant melanoma at the exposed site on the scalp." | 3.69 | Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. ( Fink-Puches, R; Kerl, H; Reimann-Weber, A; Wolf, P, 1997) |
| "With regard to squamous cell carcinoma, treatment with 5-fluorouracil, methotrexate, interferon, and bleomycin are reviewed." | 2.47 | Intralesional agents in the management of cutaneous malignancy: a review. ( Good, LM; High, WA; Miller, MD, 2011) |
| "5-Aminolevulinic acid is a prodrug clinically approved for PDT." | 1.91 | Enhanced Delivery of 5-Aminolevulinic Acid by Lecithin Invasomes in 3D Melanoma Cancer Model. ( Caputo, A; Filotico, R; Gaballo, A; Gallo, N; Guida, G; Nito, A; Nobile, C; Piccirillo, C; Quarta, A; Ragusa, A; Salvatore, L; Zito, A, 2023) |
| "Silver nanoparticles were synthesised using the bacterial strain Bacillus licheniformis." | 1.51 | Photodynamic therapy on skin melanoma and epidermoid carcinoma cells using conjugated 5-aminolevulinic acid with microbial synthesised silver nanoparticles. ( Sanjay, KR; Shivashankarappa, A, 2019) |
| "5-aminolevulinic acid (5-ALA) is a drug currently used for PDT and is a hydrophilic molecule at its physiological pH, and this limits its capacity to cross the stratum corneum of skin." | 1.43 | A Formulation Study of 5-Aminolevulinic Encapsulated in DPPC Liposomes in Melanoma Treatment. ( Chen, CL; Chou, CY; Huang, YB; Hung, SY; Lin, MW; Wu, PC, 2016) |
| "Metastatic skin cancer cells SKMEL-30 were treated by 5-ALA in dark and then they were irradiated by 90-femtosecond (fs) laser with different pulse powers for different durations." | 1.40 | Femtosecond laser induced photodynamic therapy on 5-ALA treated SKMEL-30 cells: an efficient theranostic strategy to combat melanoma. ( Gündoğdu, Y; Kara, R; Kars, MD; Kepceoğlu, A; Kılıç, HŞ, 2014) |
| "Melanotic melanomas have a poor response to photodynamic therapy (PDT)." | 1.34 | A new method for photodynamic therapy of melanotic melanoma -- effects of depigmentation with violet light photodynamic therapy. ( Iani, V; Ma, LW; Moan, J; Nielsen, KP, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.50) | 18.7374 |
| 1990's | 6 (15.00) | 18.2507 |
| 2000's | 8 (20.00) | 29.6817 |
| 2010's | 20 (50.00) | 24.3611 |
| 2020's | 5 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| McEwan, C | 1 |
| Nesbitt, H | 1 |
| Nicholas, D | 1 |
| Kavanagh, ON | 1 |
| McKenna, K | 1 |
| Loan, P | 1 |
| Jack, IG | 1 |
| McHale, AP | 1 |
| Callan, JF | 1 |
| Marhold, F | 1 |
| Roetzer-Pejrimovsky, T | 1 |
| Scheichel, F | 1 |
| Mercea, PA | 1 |
| Mischkulnig, M | 1 |
| Wadiura, LI | 1 |
| Kiesel, B | 1 |
| Weber, M | 1 |
| Popadic, B | 1 |
| Prihoda, R | 1 |
| Hafner, C | 1 |
| Widhalm, G | 1 |
| Gaballo, A | 1 |
| Ragusa, A | 1 |
| Nobile, C | 1 |
| Gallo, N | 1 |
| Salvatore, L | 1 |
| Piccirillo, C | 1 |
| Nito, A | 1 |
| Caputo, A | 1 |
| Guida, G | 1 |
| Zito, A | 1 |
| Filotico, R | 1 |
| Quarta, A | 1 |
| Zhang, L | 1 |
| Ji, Z | 1 |
| Zhang, J | 1 |
| Yang, S | 1 |
| Naidoo, C | 1 |
| Kruger, CA | 1 |
| Abrahamse, H | 2 |
| Leviskas, B | 1 |
| Valyi-Nagy, T | 1 |
| Munirathinam, G | 1 |
| Bork, M | 1 |
| Valyi-Nagy, K | 1 |
| Skwor, T | 1 |
| Hasegawa, T | 1 |
| Takahashi, J | 1 |
| Nagasawa, S | 1 |
| Doi, M | 1 |
| Moriyama, A | 1 |
| Iwahashi, H | 1 |
| Sheehan, D | 1 |
| Sheehan, K | 1 |
| Sheehan, J | 1 |
| Cai, J | 1 |
| Zheng, Q | 1 |
| Huang, H | 1 |
| Li, B | 1 |
| Ruschel, LG | 1 |
| Ramina, R | 1 |
| da Silva, EB | 1 |
| Cavalcanti, MS | 1 |
| Duarte, JFS | 1 |
| Shivashankarappa, A | 1 |
| Sanjay, KR | 1 |
| Ferreira, DM | 1 |
| Saga, YY | 1 |
| Aluicio-Sarduy, E | 1 |
| Tedesco, AC | 2 |
| Mohammadi, Z | 1 |
| Sazgarnia, A | 1 |
| Rajabi, O | 1 |
| Soudmand, S | 1 |
| Esmaily, H | 1 |
| Sadeghi, HR | 1 |
| Dixon, AJ | 1 |
| Anderson, SJ | 1 |
| Mazzurco, JD | 1 |
| Steinman, HK | 1 |
| Kars, MD | 1 |
| Kara, R | 1 |
| Gündoğdu, Y | 1 |
| Kepceoğlu, A | 1 |
| Kılıç, HŞ | 1 |
| Wang, S | 1 |
| Hu, Z | 1 |
| Wang, X | 1 |
| Gu, C | 1 |
| Gao, Z | 1 |
| Cao, W | 1 |
| Zheng, J | 1 |
| Tarstedt, M | 1 |
| Gillstedt, M | 1 |
| Wennberg Larkö, AM | 1 |
| Paoli, J | 1 |
| Lin, MW | 1 |
| Huang, YB | 1 |
| Chen, CL | 1 |
| Wu, PC | 2 |
| Chou, CY | 1 |
| Hung, SY | 1 |
| Shokeen, D | 1 |
| Tsai, T | 1 |
| Ji, HT | 1 |
| Chiang, PC | 1 |
| Chou, RH | 1 |
| Chang, WS | 1 |
| Chen, CT | 1 |
| Good, LM | 1 |
| Miller, MD | 1 |
| High, WA | 1 |
| Robertson, CA | 1 |
| Evans, D | 1 |
| Schucht, P | 1 |
| Beck, J | 1 |
| Vajtai, I | 1 |
| Raabe, A | 1 |
| Kamp, MA | 1 |
| Grosser, P | 1 |
| Felsberg, J | 1 |
| Slotty, PJ | 1 |
| Steiger, HJ | 1 |
| Reifenberger, G | 1 |
| Sabel, M | 1 |
| Alloo, A | 1 |
| Garibyan, L | 1 |
| LeBoeuf, N | 1 |
| Lin, G | 1 |
| Werchniak, A | 1 |
| Hodi, FS | 1 |
| Flaherty, KT | 1 |
| Lawrence, DP | 1 |
| Lin, JY | 1 |
| Shrestha, TB | 1 |
| Seo, GM | 1 |
| Basel, MT | 1 |
| Kalita, M | 1 |
| Wang, H | 1 |
| Villanueva, D | 1 |
| Pyle, M | 1 |
| Balivada, S | 1 |
| Rachakatla, RS | 1 |
| Shinogle, H | 1 |
| Thapa, PS | 1 |
| Moore, D | 1 |
| Troyer, DL | 1 |
| Bossmann, SH | 1 |
| Vena, FC | 1 |
| Turchiello, RF | 1 |
| Laville, I | 1 |
| Pigaglio, S | 1 |
| Blais, J | 1 |
| Córdoba, F | 1 |
| Braathen, LR | 1 |
| Weissenberger, J | 1 |
| Vallan, C | 1 |
| Kato, M | 1 |
| Nakashima, I | 1 |
| Weis, J | 1 |
| von Felbert, V | 1 |
| Schacht, V | 1 |
| Szeimies, RM | 2 |
| Abels, C | 2 |
| Frank, J | 1 |
| Lornejad-Schäfer, MR | 1 |
| Schöffl, H | 1 |
| Flaccus, A | 1 |
| Lambert, C | 1 |
| Biesalski, HK | 1 |
| Ma, LW | 1 |
| Nielsen, KP | 1 |
| Iani, V | 1 |
| Moan, J | 1 |
| Grabowska, AM | 1 |
| Piskorska, D | 1 |
| Winter, R | 1 |
| Iinuma, S | 1 |
| Farshi, SS | 1 |
| Ortel, B | 1 |
| Hasan, T | 1 |
| Sterenborg, HJ | 1 |
| Saarnak, AE | 1 |
| Frank, R | 1 |
| Motamedi, M | 1 |
| Wolf, P | 2 |
| Fink-Puches, R | 2 |
| Reimann-Weber, A | 1 |
| Kerl, H | 2 |
| Fritsch, C | 2 |
| Goetz, AE | 1 |
| Stahl, W | 1 |
| Bolsen, K | 1 |
| Ruzicka, T | 1 |
| Goerz, G | 1 |
| Sies, H | 2 |
| Soyer, HP | 1 |
| Hofer, A | 1 |
| Klotz, LO | 1 |
| Briviba, K | 1 |
| Tsacmacidis, N | 1 |
| Schliess, F | 1 |
| Prasmickaite, L | 1 |
| Høgset, A | 1 |
| Berg, K | 1 |
| Karrer, S | 1 |
| Hohenleutner, U | 1 |
| Landthaler, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center Phase II Trial of Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation[NCT01474551] | Phase 2 | 2 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Lack of accrual) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 will be used to determine treatment response. In order to be considered evaluable for response, a patient must have completed at least 1 cycle of therapy. Patients who do not complete a cycle of therapy can be replaced. (NCT01474551)
Timeframe: 2 years
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Stable Disease | Complete Response | Partial Response | Progression of Disease | |
| Vemurafenib | 1 | 0 | 0 | 0 |
4 reviews available for aminolevulinic acid and Malignant Melanoma
| Article | Year |
|---|---|
Simultaneous Photodiagnosis and Photodynamic Treatment of Metastatic Melanoma.
Topics: Aminolevulinic Acid; Anthracenes; Biopsy, Fine-Needle; Drug Carriers; Early Diagnosis; Humans; Indol | 2019 |
Chitosan nanoparticles for melanoma cancer treatment by Photodynamic Therapy and electrochemotherapy using aminolevulinic acid derivatives.
Topics: Aminolevulinic Acid; Chitosan; Drug Delivery Systems; Electrochemotherapy; Humans; Melanoma; Nanopar | 2013 |
Intralesional agents in the management of cutaneous malignancy: a review.
Topics: Aminolevulinic Acid; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bleomycin; Carci | 2011 |
Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy.
Topics: Aged; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinica | 2001 |
3 trials available for aminolevulinic acid and Malignant Melanoma
| Article | Year |
|---|---|
Novel photodynamic therapy does not prevent new skin cancers--randomized controlled trial.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Facial Neoplasms; Female | 2014 |
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease Progression; Dru | 2012 |
Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Carcin | 1998 |
33 other studies available for aminolevulinic acid and Malignant Melanoma
| Article | Year |
|---|---|
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
Topics: Aminolevulinic Acid; Animals; Heterografts; Humans; Melanoma; Mice, SCID; Photochemotherapy; Skin Ne | 2016 |
Does pigmentation, hemosiderin and blood effect visible 5-ALA fluorescence in cerebral melanoma metastasis?
Topics: Adult; Aminolevulinic Acid; Brain Neoplasms; Hemosiderin; Humans; Melanins; Melanoma; Photochemother | 2022 |
Enhanced Delivery of 5-Aminolevulinic Acid by Lecithin Invasomes in 3D Melanoma Cancer Model.
Topics: Aminolevulinic Acid; Humans; Lecithins; Limonene; Melanoma; Melanoma, Cutaneous Malignant; Photochem | 2023 |
Photodynamic therapy enhances skin cancer chemotherapy effects through autophagy regulation.
Topics: Adenine; Aminolevulinic Acid; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferat | 2019 |
Metalloporphyrin Pd(T4) Exhibits Oncolytic Activity and Cumulative Effects with 5-ALA Photodynamic Treatment against C918 Cells.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; | 2020 |
DNA Strand Break Properties of Protoporphyrin IX by X-Ray Irradiation against Melanoma.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; DNA Breaks, Double-Stranded; Melanoma; Mice; Protopo | 2020 |
Sonodynamic therapy for metastatic melanoma to the brain.
Topics: Aminolevulinic Acid; Brain; Brain Neoplasms; Humans; Melanoma | 2021 |
5-aminolevulinic acid mediated photodynamic therapy inhibits survival activity and promotes apoptosis of A375 and A431 cells.
Topics: Aminolevulinic Acid; Apoptosis; bcl-2-Associated X Protein; Caspases; Cell Line, Tumor; Cell Surviva | 2018 |
5-Aminolevulinic acid fluorescence-guided surgery for spinal cord melanoma metastasis: a technical note.
Topics: Adult; Aminolevulinic Acid; Brain Neoplasms; Ependymoma; Female; Fluorescent Dyes; Humans; Male; Mel | 2018 |
Photodynamic therapy on skin melanoma and epidermoid carcinoma cells using conjugated 5-aminolevulinic acid with microbial synthesised silver nanoparticles.
Topics: Aminolevulinic Acid; Animals; Bacillus licheniformis; Carcinoma, Squamous Cell; Cell Line, Tumor; Hu | 2019 |
An in vitro study on the photosensitivity of 5-aminolevulinic acid conjugated gold nanoparticles.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Radiation; Gold; H | 2013 |
Femtosecond laser induced photodynamic therapy on 5-ALA treated SKMEL-30 cells: an efficient theranostic strategy to combat melanoma.
Topics: Aged; Aminolevulinic Acid; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Fluorescence; Human | 2014 |
5-Aminolevulinic acid-mediated sonodynamic therapy reverses macrophage and dendritic cell passivity in murine melanoma xenografts.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dendritic | 2014 |
Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studie | 2016 |
A Formulation Study of 5-Aminolevulinic Encapsulated in DPPC Liposomes in Melanoma Treatment.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Aminolevulinic Acid; Animals; Cell Line, Tumor; Cell Survival; L | 2016 |
Update on new drugs in dermatology.
Topics: Aminolevulinic Acid; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agent | 2016 |
ALA-PDT results in phenotypic changes and decreased cellular invasion in surviving cancer cells.
Topics: Adenocarcinoma; Aminolevulinic Acid; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Down-Regulat | 2009 |
The in vitro PDT efficacy of a novel metallophthalocyanine (MPc) derivative and established 5-ALA photosensitizing dyes against human metastatic melanoma cells.
Topics: Aminolevulinic Acid; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Survival; H | 2010 |
Paradoxical fluorescence after administration of 5-aminolevulinic acid for resection of a cerebral melanoma metastasis.
Topics: Aged; Aminolevulinic Acid; Brain Neoplasms; Humans; Male; Melanoma; Microscopy, Fluorescence; Skin N | 2011 |
5-aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Carcinoma; Female; Fl | 2012 |
Stem cell-based photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Cell Survival; Female; Fetal Blood; Imidazoles; Luci | 2012 |
5-aminolevulinic acid ester-induced protoporphyrin IX in a murine melanoma cell line.
Topics: Aminolevulinic Acid; Animals; Diffusion; Dose-Response Relationship, Drug; Magnetic Resonance Spectr | 2004 |
5-aminolaevulinic acid photodynamic therapy in a transgenic mouse model of skin melanoma.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Fibrosis; Flo | 2005 |
Photodynamic therapy with 5-aminolevulinic acid induces distinct microcirculatory effects following systemic or topical application.
Topics: Aminolevulinic Acid; Animals; Capillaries; Cricetinae; Male; Melanoma; Mesocricetus; Microcirculatio | 2006 |
Inhibition of heme oxygenase-1 increases responsiveness of melanoma cells to ALA-based photodynamic therapy.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Enzyme Inhibitors; Heme Oxygenase-1; Humans; Melanoma; Metall | 2007 |
A new method for photodynamic therapy of melanotic melanoma -- effects of depigmentation with violet light photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Female; Humans; Light; Melanoma; Mice; Mice, Nude; Neoplasm Transplant | 2007 |
[Biosynthesis of liver porphyrins in the Syrian hamster under the effect of toxohormone, endogenic or isolated from melanoma].
Topics: Aminolevulinic Acid; Animals; Catalase; Cricetinae; Endotoxins; In Vitro Techniques; Liver; Male; Me | 1980 |
A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Division; | 1994 |
Evaluation of spectral correction techniques for fluorescence measurements on pigmented lesions in vivo.
Topics: Adult; Aminolevulinic Acid; Humans; Male; Melanoma; Sensitivity and Specificity; Spectrometry, Fluor | 1996 |
Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site.
Topics: Aged; Aged, 80 and over; Alopecia; Aminolevulinic Acid; Carcinoma, Squamous Cell; Follow-Up Studies; | 1997 |
Porphyrins preferentially accumulate in a melanoma following intravenous injection of 5-aminolevulinic acid.
Topics: Aminolevulinic Acid; Animals; Cricetinae; Disease Models, Animal; Erythrocytes; Injections, Intraven | 1997 |
Activation of JNK and p38 but not ERK MAP kinases in human skin cells by 5-aminolevulinate-photodynamic therapy.
Topics: Aminolevulinic Acid; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; Cell Survival; Enzyme | 1998 |
Evaluation of different photosensitizers for use in photochemical gene transfection.
Topics: Aminolevulinic Acid; Animals; DNA; Endocytosis; Endosomes; Fatty Acids, Monounsaturated; Gene Transf | 2001 |